AU2006265281C1 - Anti-CCR7 receptor antibodies for the treatment of cancer - Google Patents

Anti-CCR7 receptor antibodies for the treatment of cancer Download PDF

Info

Publication number
AU2006265281C1
AU2006265281C1 AU2006265281A AU2006265281A AU2006265281C1 AU 2006265281 C1 AU2006265281 C1 AU 2006265281C1 AU 2006265281 A AU2006265281 A AU 2006265281A AU 2006265281 A AU2006265281 A AU 2006265281A AU 2006265281 C1 AU2006265281 C1 AU 2006265281C1
Authority
AU
Australia
Prior art keywords
cells
ccr7
antibody
antibodies
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006265281A
Other languages
English (en)
Other versions
AU2006265281B2 (en
AU2006265281A1 (en
Inventor
Manuel Jesus Alfonso Perez
Sonia Lopez Giral
Cecilia Munoz Calleja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autonomous University of Madrid
Original Assignee
Autonomous University of Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autonomous University of Madrid filed Critical Autonomous University of Madrid
Publication of AU2006265281A1 publication Critical patent/AU2006265281A1/en
Publication of AU2006265281B2 publication Critical patent/AU2006265281B2/en
Application granted granted Critical
Publication of AU2006265281C1 publication Critical patent/AU2006265281C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006265281A 2005-07-06 2006-07-05 Anti-CCR7 receptor antibodies for the treatment of cancer Ceased AU2006265281C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/EP2005/007371 2005-07-06
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
PCT/EP2006/006556 WO2007003426A1 (en) 2005-07-06 2006-07-05 Anti-ccr7 receptor antibodies for the treatment of cancer

Publications (3)

Publication Number Publication Date
AU2006265281A1 AU2006265281A1 (en) 2007-01-11
AU2006265281B2 AU2006265281B2 (en) 2012-03-01
AU2006265281C1 true AU2006265281C1 (en) 2012-11-15

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006265281A Ceased AU2006265281C1 (en) 2005-07-06 2006-07-05 Anti-CCR7 receptor antibodies for the treatment of cancer

Country Status (16)

Country Link
US (1) US8066996B2 (cg-RX-API-DMAC10.html)
EP (1) EP1904102B1 (cg-RX-API-DMAC10.html)
JP (1) JP5249025B2 (cg-RX-API-DMAC10.html)
KR (1) KR20080030655A (cg-RX-API-DMAC10.html)
CN (1) CN101257923A (cg-RX-API-DMAC10.html)
AT (1) ATE453407T1 (cg-RX-API-DMAC10.html)
AU (1) AU2006265281C1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0612632A2 (cg-RX-API-DMAC10.html)
CA (1) CA2614080C (cg-RX-API-DMAC10.html)
DE (1) DE602006011466D1 (cg-RX-API-DMAC10.html)
DK (1) DK1904102T3 (cg-RX-API-DMAC10.html)
ES (1) ES2338919T3 (cg-RX-API-DMAC10.html)
IL (1) IL188594A (cg-RX-API-DMAC10.html)
PT (1) PT1904102E (cg-RX-API-DMAC10.html)
RU (1) RU2404808C2 (cg-RX-API-DMAC10.html)
WO (2) WO2007003216A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
WO2009139853A2 (en) * 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
JP5801202B2 (ja) * 2009-09-29 2015-10-28 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
JP5315495B2 (ja) * 2010-09-28 2013-10-16 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6469644B2 (ja) 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
KR102663440B1 (ko) * 2015-08-10 2024-05-07 펩맵 비.브이. 인간화된 항-ccr7 리셉터 항체
JP2018530560A (ja) 2015-10-09 2018-10-18 サレプタ セラピューティクス， インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
JP2022514867A (ja) * 2018-12-18 2022-02-16 カタパルト セラピューティクス ビー．ヴイ． 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255112A2 (en) * 2001-04-30 2002-11-06 Pfizer Products Inc. Treatment of T-cell mediated diseases
US20040185507A1 (en) * 2000-08-07 2004-09-23 Jill Giles-Komar Anti-integrin antibodies, compositions, methods and uses
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
ATE382372T1 (de) * 2003-06-11 2008-01-15 Univ Chicago Erhöhte t-zell tumor-eindringung durch light- mutanten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185507A1 (en) * 2000-08-07 2004-09-23 Jill Giles-Komar Anti-integrin antibodies, compositions, methods and uses
EP1255112A2 (en) * 2001-04-30 2002-11-06 Pfizer Products Inc. Treatment of T-cell mediated diseases
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORCIONE, A. et al. Clinical Cancer Research. 2004, vol. 10, pages 964-971 *
GHOBRIAL,I.M. et al. Mayo Clinic Proceedings. 2004, vol. 79, pages 318-325 *
LOPEZ-GIRAL, S. et al. Journal of Leukocyte Biology. 2004, vol. 76 pages 462- 471 *
TILL, K.J. et al. Blood. 2002. vol. 99 pages 2977-2984 *

Also Published As

Publication number Publication date
IL188594A (en) 2012-02-29
CN101257923A (zh) 2008-09-03
AU2006265281B2 (en) 2012-03-01
BRPI0612632A2 (pt) 2012-01-03
EP1904102B1 (en) 2009-12-30
DK1904102T3 (da) 2010-04-19
ATE453407T1 (de) 2010-01-15
CA2614080A1 (en) 2007-01-11
US8066996B2 (en) 2011-11-29
WO2007003426A1 (en) 2007-01-11
AU2006265281A1 (en) 2007-01-11
JP2008545000A (ja) 2008-12-11
WO2007003216A1 (en) 2007-01-11
US20090123483A1 (en) 2009-05-14
PT1904102E (pt) 2010-03-29
IL188594A0 (en) 2008-04-13
CA2614080C (en) 2014-08-26
EP1904102A1 (en) 2008-04-02
KR20080030655A (ko) 2008-04-04
RU2008104420A (ru) 2009-08-20
JP5249025B2 (ja) 2013-07-31
DE602006011466D1 (de) 2010-02-11
ES2338919T3 (es) 2010-05-13
RU2404808C2 (ru) 2010-11-27

Similar Documents

Publication Publication Date Title
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
US9862767B2 (en) Therapeutic methods using anti-CD200 antibodies
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
KR102338832B1 (ko) Ccr9에 대한 항체 및 그의 적용방법
US20260001958A1 (en) Medicaments, uses and methods
AU2002236519A1 (en) Methods for the prevention and treatment of cancer using anti-C3B(i) antibodies
CN1981868A (zh) 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
CN110997724A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
KR20240040097A (ko) Cd3 표적화 항체 및 이의 용도
CA2400488A1 (en) Methods for the prevention and treatment of infections using anti-c3b(i) antibodies
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
HK1255020A1 (en) Humanized anti-ccr7 receptor antibodies
HK1255020B (en) Humanized anti-ccr7 receptor antibodies

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 MAY 2012 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 MAY 2012

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired